Patents by Inventor Tomoe Matsumoto

Tomoe Matsumoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VEGF-binding KDR polypeptide
    Patent number: 6348333
    Abstract: A novel polypeptide is provided, which can be utilized to treat diseases accompanying neovascularization, such as solid tumors, and is useful as a low molecular weight VEGF inhibitor. The polypeptide contains immunoglobulin-like domain 1 and immunoglobulin-like domain 2 of the extracellular domain of the VEGF receptor KDR. Since it has smaller molecular weight than the conventional polypeptides with retaining VEGF inhibitory activity, it is expected that it can be readily expressed using recombinant DNA techniques and infiltrates into diseased sites more quickly.
    Type: Grant
    Filed: March 4, 1999
    Date of Patent: February 19, 2002
    Assignee: Toa Gosei Co., Ltd.
    Inventors: Mikio Niwa, Masaji Okamoto, Tomoe Matsumoto, Toshiaki Segawa
  • VEGF-binding polypeptide
    Patent number: 6270993
    Abstract: An object of the present invention is to provide a low molecular weight VEGF inhibitor that can be utilized to treat diseases accompanying neovascularization, such as solid tumors. It was found that a polypeptide containing immunoglobulin-like domain 1 and immunoglobulin-like domain 2 but neither immunoglobulin-like main 6 nor immunoglobulin-like domain 7 of the extracellular domain of the VEGF receptor FLT possess VEGF inhibitory activity.
    Type: Grant
    Filed: July 15, 1998
    Date of Patent: August 7, 2001
    Assignee: Toa Gosei Co., Ltd.
    Inventors: Masabumi Shibuya, Masaji Okamoto, Mikio Niwa, Tomoe Matsumoto, Makoto Asano, Tosiaki Segawa
  • Peptides and monoclonal antibodies
    Patent number: 6024955
    Abstract: A peptide corresponding to a portion of human vascular permeability factor (VPF) and a VPF monoclonal antibody recognizing the peptide are provided. The peptide of the invention is useful as an antigen for preparing a monoclonal antibody against VPF and as a reagent for biochemical analysis. The monoclonal antibody of the invention reactive with the above peptide is useful not only as a reagent for biochemical analysis but also as a diagnostic agent or therapeutic agent for various diseases such as cancer.
    Type: Grant
    Filed: October 31, 1996
    Date of Patent: February 15, 2000
    Assignee: Toagosei Co. Ltd.
    Inventors: Makoto Asano, Ayako Yukita, Mitsuya Hanatani, Tomoe Matsumoto, Masaji Okamoto, Hideo Suzuki